Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Esperion Theraptc
(NQ:
ESPR
)
2.130
-0.120 (-5.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Esperion Theraptc
< Previous
1
2
3
Next >
Esperion to Participate in Jefferies London Healthcare Conference
October 31, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Third Quarter 2023 Financial Results on November 7
October 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
American College of Cardiology Program to Increase Cholesterol Screenings
September 12, 2023
From
Esperion Therapeutics, Inc.; The American College of Cardiology
Via
GlobeNewswire
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
August 26, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
August 11, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports Second Quarter 2023 Financial Results
August 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in BTIG Virtual Biotechnology Conference 2023
July 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Second Quarter 2023 Financial Results on August 1
July 17, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023
July 07, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet
June 28, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
June 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023
June 15, 2023
Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed...
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
June 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
June 05, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
June 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
May 25, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Jefferies Healthcare Conference
May 24, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 12, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Reports First Quarter 2023 Financial Results
May 09, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
May 04, 2023
– Gibson Dunn Files Amended Complaint with Powerful New Evidence –
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in JMP Securities Life Sciences Conference
May 01, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
April 27, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
April 25, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
April 19, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
April 03, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 22, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 20, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
March 08, 2023
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.